What are examples of medium potency topical corticosteroids?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medium Potency Topical Corticosteroids

Medium potency topical corticosteroids include clocortolone pivalate 0.1%, clobetasone butyrate 0.05%, betamethasone valerate 0.025%, and fluocinolone acetonide 0.025%. 1, 2, 3

Classification of Medium Potency Corticosteroids

Medium potency topical corticosteroids (Classes 3-4) are positioned between high potency (Classes 1-2) and low potency (Classes 5-7) preparations in the corticosteroid potency spectrum. They offer a balance between efficacy and safety profile.

Examples of Medium Potency Topical Corticosteroids:

  • Class 3-4 (Medium Potency):
    • Clocortolone pivalate 0.1% (Cloderm) 1
    • Clobetasone butyrate 0.05% (Eumovate) 2
    • Betamethasone valerate 0.025% (Betnovate-RD) 2
    • Fluocinolone acetonide 0.025% 4
    • Triamcinolone acetonide 0.1% 4
    • Hydrocortisone butyrate 0.1% 2

Efficacy and Applications

Medium potency topical corticosteroids demonstrate good clinical efficacy with reported improvement rates of 68-72% in conditions like psoriasis and atopic dermatitis 3. They are particularly useful for:

  • Maintenance therapy in atopic dermatitis (twice weekly application) 2
  • Moderate cases of psoriasis with noticeable scaling 3
  • Areas where higher potency steroids might cause adverse effects
  • Intermediate-term treatment (up to 12 weeks) 5

Formulations

Medium potency corticosteroids are available in various formulations:

  • Creams (suitable for weeping lesions)
  • Ointments (better for dry skin conditions)
  • Lotions and solutions (for scalp application)

Safety Profile and Precautions

Medium potency corticosteroids have a more favorable safety profile than high potency preparations but still require careful use:

  • Can be used for up to 12 weeks, compared to 3 weeks maximum for super-high potency steroids 5
  • Should be used with caution on thin skin areas (face, intertriginous areas)
  • Risk of local side effects (skin atrophy, telangiectasia, striae) is lower than with high potency steroids but still present with prolonged use 2
  • Tachyphylaxis (decreased effectiveness with continued use) may occur with long-term application 2

Application Guidelines

  • Apply once or twice daily as directed
  • Use the fingertip unit method for appropriate dosing (one fingertip unit covers approximately 2% body surface area) 5
  • Consider gradual reduction in usage following clinical response 2
  • For maintenance therapy in atopic dermatitis, twice weekly application is recommended 2

Comparison to Other Potency Classes

Potency Class Examples Maximum Duration Efficacy Rate
Class 1-2 (High/Very High) Clobetasol propionate 0.05%, Betamethasone dipropionate 0.05% 2-4 weeks 58-92%
Class 3-4 (Medium) Clocortolone pivalate 0.1%, Clobetasone butyrate 0.05% Up to 12 weeks 68-72%
Class 5-7 (Low) Hydrocortisone 1-2.5% No specific time limit 41-83%

Medium potency corticosteroids provide an important middle ground in topical steroid therapy, balancing efficacy with a reduced risk of adverse effects compared to high potency preparations.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Corticosteroid Use in Psoriasis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Relative Potency of Topical Corticosteroid Preparations.

Indian journal of dermatology, venereology and leprology, 1985

Research

Topical Corticosteroids: Choice and Application.

American family physician, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.